神經生物標記市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、最終用戶、地區和競爭細分，2020-2030 年預測

2024 年全球神經生物標記市場價值為 87 億美元，預計在預測期內將經歷大幅成長，到 2030 年的複合年成長率為 8.10%。神經生物標記是診斷、監測和研究中樞神經系統和周邊神經系統的神經系統疾病的重要工具。近年來，市場經歷了顯著的成長，其促進因素包括生物標記在現代醫學和研究中的關鍵作用。受神經系統疾病盛行率不斷上升、生物標記發現和驗證的進步以及老齡化人口日益成長的影響，該行業預計將繼續擴張。隨著神經系統疾病變得越來越普遍，對早期、準確診斷工具的需求激增，從而推動了市場成長。

主要市場促進因素

神經系統疾病盛行率不斷上升

主要市場挑戰

神經系統疾病的複雜性

主要市場趨勢

個性化醫療的興起

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：神經生物標記市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型（影像、蛋白質體學、基因體學、代謝體學、其他）
  • 依應用分類（多發性硬化症、阿茲海默症、自閉症譜系障礙、帕金森氏症等）
  • 按最終使用者（研究機構、醫院及醫院實驗室、獨立臨床診斷中心等）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美神經生物標記市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲神經生物標記市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區神經生物標記市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲神經生物標記市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲神經生物標記市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球神經生物標記市場：SWOT 分析

第 14 章：競爭格局

• PERKINELMER INC.
• Abbott Laboratories Inc
• Thermo Fisher Scientific, Inc.
• Banyan Biomarkers, Inc.
• Bio-Rad Laboratories, Inc.
• F. HOFFMANN-LA ROCHE LTD.
• Merck & Co., Inc.
• DiaGenic ASA
• Johnson & Johnson Services, Inc.
• Myriad Genetics, Inc

第 15 章：策略建議

第16章 關於出版商,免責事項

The Global Neurological Biomarkers Market was valued at USD 8.70 billion in 2024 and is projected to experience substantial growth during the forecast period, with a CAGR of 8.10% through 2030. This market represents a dynamic and rapidly advancing segment within the healthcare and life sciences industry. Neurological biomarkers are essential tools used for diagnosing, monitoring, and researching neurological disorders that affect both the central and peripheral nervous systems. The market has experienced significant growth in recent years, driven by factors that highlight the critical role of biomarkers in modern medicine and research. The sector is expected to continue its expansion, influenced by increasing prevalence of neurological disorders, advances in biomarker discovery and validation, and a growing aging population. As neurological conditions become more widespread, the demand for early, accurate diagnostic tools has surged, fueling market growth.

Key Market Drivers

Increasing Prevalence of Neurological Disorders

The growing incidence of neurological disorders globally plays a significant role in shaping the Neurological Biomarkers Market. As conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, stroke, and traumatic brain injuries become more common, the need for advanced diagnostic tools, early detection methods, and precision treatment solutions has risen. Neurological biomarkers are critical in meeting these needs and driving market growth. These disorders are major contributors to disability and mortality worldwide, affecting over one in three individuals. In 2021, stroke was identified as the leading cause of health loss among the top neurological conditions. This rising disease burden has emphasized the need for early and accurate diagnostic solutions, thereby increasing the demand for neurological biomarkers.

The global aging population has resulted in an increase in neurodegenerative diseases, particularly Alzheimer's. The global dementia population is expected to nearly double every 20 years, reaching 78 million by 2030 and 139 million by 2050. A large proportion of this growth is expected in developing countries, where dementia prevalence is rapidly rising. Currently, 60% of dementia cases occur in low- and middle-income nations, with this figure projected to rise to 71% by 2050, underscoring the urgent need for expanded healthcare infrastructure, diagnostic capabilities, and intervention strategies in these regions. Biomarkers are increasingly incorporated into diagnostic protocols to detect Alzheimer's at early or pre-symptomatic stages.

In the United States, approximately one million individuals are diagnosed with Parkinson's disease (PD), and this number is expected to increase to 1.2 million by 2030. As the second most prevalent neurodegenerative disorder after Alzheimer's, Parkinson's presents a growing public health challenge, driving demand for advanced diagnostics, early detection, and innovative treatment solutions. Additionally, approximately one in four adults worldwide is at risk of experiencing a stroke, with over 12 million individuals expected to have their first stroke this year, leading to an anticipated 6.5 million fatalities. More than 100 million people globally are living with the long-term effects of stroke, highlighting the urgent need for improved prevention, early detection, and treatment options. Neurological biomarkers such as glial fibrillary acidic protein (GFAP) and S100B are widely used in stroke detection and brain injury assessment, further driving market growth. As more healthcare providers adopt biomarker-based diagnostic tests, the market continues to expand.

Key Market Challenges

Complexity of Neurological Disorders

A significant challenge in the development and adoption of neurological biomarkers is the complexity of neurological disorders. These conditions span a wide range of diseases, each with its unique characteristics and mechanisms. Disorders such as Alzheimer's, Parkinson's, and multiple sclerosis exhibit considerable heterogeneity among patients, making it difficult to identify universal biomarkers applicable to all cases. This complexity necessitates the discovery and validation of diverse biomarkers, a process that can be both time-consuming and resource-intensive. Furthermore, the concept of precision medicine, which tailors treatment to individual patients based on their unique biomarker profiles, complicates the development of standardized biomarkers. Customized biomarker panels may be required for each patient, increasing the need for personalized medicine approaches.

Key Market Trends

Rise of Personalized Medicine

A key trend in the Global Neurological Biomarkers Market is the shift toward personalized medicine, which involves tailoring medical treatments to individual patients based on their genetic, biomarker, and clinical profiles. This trend is fueled by advances in genomics and biomarker technologies, which allow for more precise disease predictions and treatment planning. The sequencing of the human genome, along with high-throughput genomics technologies, has enabled the identification of genetic variations associated with neurological disorders. These genetic biomarkers are used to assess disease risk and develop personalized treatment strategies. Additionally, biomarker panels that incorporate genetic, proteomic, and imaging data are being developed to provide more accurate diagnoses and differentiate between various subtypes of neurological disorders.

Personalized medicine enhances treatment effectiveness by selecting therapies that are most likely to work for individual patients, thereby minimizing the risk of adverse effects and optimizing therapeutic outcomes.

Key Market Players

• PerkinElmer Inc.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Banyan Biomarkers Inc.
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• DiaGenic ASA
• Johnson & Johnson Services Inc.
• Myriad Genetics Inc.

Report Scope

This report segments the Global Neurological Biomarkers Market into the following categories, in addition to detailing the industry trends:

Neurological Biomarkers Market, by Type:

• Imaging
• Proteomic
• Genomic
• Metabolomic
• Others

Neurological Biomarkers Market, by Application:

• Multiple Sclerosis
• Alzheimer's Disease
• Autism Spectrum Disorder
• Parkinson's Disease
• Others

Neurological Biomarkers Market, by End-User:

• Research Organizations
• Hospitals and Hospital Laboratories
• Independent Clinical Diagnostic Centers
• Others

Neurological Biomarkers Market, by Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia-Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

The report includes detailed company profiles of the major players in the Global Neurological Biomarkers Market.

Available Customizations:

This report on the Global Neurological Biomarkers Market includes customized options to cater to a company's specific needs. The following customizations are available:

• Company Information: Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Neurological Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Imaging, Proteomic, Genomic, Metabolomic, Others)
  • 5.2.2. By Application (Multiple Sclerosis, Alzheimer's Disease, Autism Spectrum Disorder, Parkinson's Disease, Others)
  • 5.2.3. By End-User (Research Organizations, Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Neurological Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neurological Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Neurological Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Neurological Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Neurological Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neurological Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Neurological Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Neurological Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Neurological Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Neurological Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Neurological Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Neurological Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Neurological Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Neurological Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Neurological Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Neurological Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Neurological Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neurological Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Neurological Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Neurological Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Neurological Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neurological Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Neurological Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Neurological Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Neurological Biomarkers Market: SWOT Analysis

14. Competitive Landscape

• 14.1. PERKINELMER INC.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Abbott Laboratories Inc
• 14.3. Thermo Fisher Scientific, Inc.
• 14.4. Banyan Biomarkers, Inc.
• 14.5. Bio-Rad Laboratories, Inc.
• 14.6. F. HOFFMANN-LA ROCHE LTD.
• 14.7. Merck & Co., Inc.
• 14.8. DiaGenic ASA
• 14.9. Johnson & Johnson Services, Inc.
• 14.10.Myriad Genetics, Inc

15. Strategic Recommendations

16. About Us & Disclaimer